ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham.

Chronic respiratory illness is associated with lung dysbiosis (abnormal lung microbiome) in addition to local and systemic inflammation. An abnormal microbiome induces further inflammation according to the company, creating a downward spiral. ResBiotic is developing first-in-class products that alleviate the neutrophilic inflammation associated with dysbiosis to improve respiratory health.

ResBiotic’s first product is a medical food that targets the gut-lung axis. The company says that the proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company’s research and development pipeline also includes pharmabiotics for multiple chronic lung diseases. These prescription probiotic treatments will be administered by nebulization, metered-dose inhaler, endotracheal tube or oral routes.

Founded in 2020, the company has raised Seed funding of $3M to help bring its first product to market in early 2022.

Subscribe for alerts on new companies featured on Startups.Bio